BIND Therapeutics

Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010.

BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nanoparticles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).

Recent News

March 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

March 10, 2015
BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

November 6, 2014
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

June 19, 2014
Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant

September 19, 2013
BIND Therapeutics Announces Pricing of Initial Public Offering

August 27, 2013
BIND Recognized by the World Economic Forum as a Technology Pioneer

August 19, 2013
BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

August 12, 2013
BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

April 22, 2013
BIND Therapeutics and AstraZeneca Announce Worldwide Development and Commercialization Agreement for Cancer Nanomedicine

April 3, 2013
BIND Therapeutics Announces Global Collaboration with Pfizer to Develop and Commercialize Multiple Accurins

January 8, 2013
BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

September 20, 2012
BIND Is Granted Five U.S. Patents Covering BIND-014 and Accurin(TM) Platform

July 16, 2012
BIND Biosciences appoints Andrew J. Hirsch as Chief Financial Officer

June 22, 2012
BIND Biosciences CEO Scott Minick and Founder Omid Farokhzad Win Ernst & Young New England Entrepreneur of the Year Award

April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

April 6, 2011
BIND Biosciences Receives 2011 Edison Award

February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

February 11, 2011
BIND Biosciences featured in the London Times

January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

June 29, 2010
BIND Biosciences Secures $12.4 Million Financing


Company Info
Country: USA
Industry:    Biotech
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP

Key persons
 Scott Minick, CEO; Dr. Robert Langer, co-founder; Dr. Omid Farokhzad, co-founder

Company website

Endeavour Vision Team
Sven Lingjaerde
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions